Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pharmena North America |
---|---|
Information provided by: | Pharmena North America |
ClinicalTrials.gov Identifier: | NCT00685737 |
The Purpose of this study is to determine the safety and tolerability of 1-MNA, a drug that is intended to be used in the treatment of elevated levels of blood fats. This study will determine the way that 1-MNA is handled by the body, and will also determine its effect on commonly measured blood fat parameters.
Condition | Intervention | Phase |
---|---|---|
Hyperlipidemia |
Drug: 1-MNA Drug: Placebo |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Randomized Placebo Controlled Double Blind Two Period Cross-Over Study to Assess the Safety and Pharmacokinetics and Pharmacodynamics of Oral Dosages of 1-MNA, (A Hypolipidemic Agent) in Healthy Volunteers |
Enrollment: | 20 |
Study Start Date: | December 2007 |
Study Completion Date: | June 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
1-MNA-Low Dose
|
Drug: 1-MNA
Capsule
|
2: Active Comparator
1-MNA-High Dose
|
Drug: 1-MNA
Capsule
|
3: Placebo Comparator
Placebo
|
Drug: Placebo
Capsule
|
Dyslipidemia is a major risk factor for coronary artery disease (CAD) and its management is important in preventing the occurrence of cardiovascular events. Dyslipidemia occurs when there is an imbalance in the metabolism and clearance of lipoproteins resulting in lipoprotein overproduction or deficiency. Lipid related risk factors for atherosclerotic coronary artery disease include elevated levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), intermediate-density lipoprotein cholesterol (IDL-C), very low-density lipoprotein cholesterol (VLDL-C) and reduced concentrations of high-density lipoprotein cholesterol (HDL-C). This lipid risk profile frequently occurs in association with other cardiovascular risk factors (e.g., obesity, elevated blood pressure, diabetes mellitus), and is associated with premature atherosclerosis (NCEP, 2002).
The Main purpose of this study is to formally evaluate the safety and pharmacokinetics and pharmacodynamics of 1-MNA, a hypolipidemic agent with previous human exposure in normal subjects and patients with Hyperlipidemia.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
Buffalo Clinical Research Center | |
Buffalo, New York, United States, 14202 |
Principal Investigator: | Charles H Ballow, Pharm D. | Buffalo Clinical Research Center |
Responsible Party: | Buffalo Clinical Research Center ( Charles Ballow, Pharm D. FACCP ) |
Study ID Numbers: | PNAI-002 |
Study First Received: | May 23, 2008 |
Last Updated: | June 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00685737 |
Health Authority: | United States: Food and Drug Administration |
Hyperlipidemia |
Metabolic Diseases Hyperlipidemias Healthy |
Metabolic disorder Dyslipidemias Lipid Metabolism Disorders |